Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer. Onkologija [Internet]. 2021 Nov. 30 [cited 2026 Sep. 2];25(2):48-53. Available from: https://revijaonkologija.si/Onkologija/article/view/473